Level B· Emerging clinical evidence with positive signalsRandomized Controlled TrialPubMedOpen access

Recombinant Platelet-Derived Growth Factor BB vs Autologous Nanofat to Enhance Recovery After CO 2 Laser and Microneedling: A Split-Face, Randomized Controlled Trial.

Claytor RB., Fuentes PM., Tolan G., Durairaj K., Quigley R., Lynch SE.

Randomized Controlled Trial on Chronic Wound, Skin Aging, Facial Rejuvenation, Chronic Inflammation, published in Aesthet Surg J Open Forum (2026) — summary generated from the PubMed abstract.

Open my reading list
Level B· Emerging clinical evidence with positive signalsEvidence level of this study

Several human studies show positive signals, while research methods and sample sizes continue to develop.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Randomized Controlled Trial
Journal
Aesthet Surg J Open Forum (2026)
Country
England
Reported sample size
—
Source database
PubMed
PMID
41890322
PMCID
PMC13015916
DOI
10.1093/asjof/ojag033

Abstract (original English)

Nanofat has been used as a "rescue" modality to support healing after CO 2 laser resurfacing with microneedling. Because demand grows for less invasive facial rejuvenation options, recombinant platelet-derived growth factor (rhPDGF-BB) has emerged as a popular adjunct to enhance postresurfacing recovery. The aim of this study was to compare autologous Nanofat to rhPDGF-BB as rescue treatments for pain and skin recovery following combined thermal and mechanical injury for improvement of facial rhytids. Five patients underwent full-face CO 2 laser treatment followed by microneedling. Each patient received split-face randomization: one side was treated with Nanofat and the contralateral side with rhPDGF-BB (300 µg/mL). Patients were blinded to allocation. Standardized 3 mm biopsies were obtained at baseline and at postprocedure Day 4, 1 month, 3 months, and 6 months and evaluated by a blinded board-certified histopathologist. Outcomes included practitioner- and patient-reported Perioral Rhytid Severity Rating Scale (PR-SRS), Global Aesthetic Improvement Scale (GAIS), and patient satisfaction. Both treatments improved patient/practitioner PR-SRS and GAIS beginning on Day 4 and continuing through 6 months. There were no significant differences between treatment groups ( P > .05). Patients reported high satisfaction with both treatment groups. Overall, histopathology assessments demo

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Several human studies show positive signals, while research methods and sample sizes continue to develop.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research